Immunotherapy is a way of treating cancer by reprogramming the patient's immune system to attack their tumor. This cutting-edge approach has significantly impacted the treatment of cancer patients, and already boasts cases ...
Jan 10, 2023
0
103
In practice guidelines issued by the American Society of Anesthesiologists and published in the January issue of Anesthesiology, recommendations are presented for reducing residual neuromuscular blockade after general anesthesia.
Jan 6, 2023
0
15
An article published in Science Advances suggests that a type of cancer treatment known as immune checkpoint blockade may be beneficial in certain cases of severe COVID-19. The creators of this therapy, which can successfully ...
Oct 27, 2022
0
72
Mount Sinai researchers have made two important discoveries about the mechanism by which bladder cancer cells foil attacks from the immune system. The research, published in Cancer Cell in September, could lead to a new therapeutic ...
Sep 12, 2022
0
67
Scientists at the Francis Crick Institute have found that using immunotherapy alongside a drug that blocks a common gene mutation in lung cancer could be a promising new combination therapy for certain types of lung tumors.
Jul 20, 2022
0
74
New research from a collaborative team at Cleveland Clinic, led by Timothy Chan, MD, Ph.D., Chair of the Center for Immunotherapy and Precision Immuno-Oncology in the Lerner Research Institute, is demonstrating that pathogenic ...
Jul 13, 2022
0
53
China has the highest morbidity of hepatocellular carcinoma (HCC) in the world. For HCC patients in early stage disease, surgical resection is the best treatment strategy, but most patients in advanced stages lose the opportunity ...
Jun 15, 2022
0
7
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from The University of Texas MD Anderson Cancer Center showed in a study published today ...
Jun 15, 2022
0
51
In a prospective phase II study that involved patients with mismatch repair–deficient locally advanced rectal cancer, treatment with neoadjuvant single-agent, PD1 inhibitor dostarlimab resulted in a clinical complete response—as ...
Jun 9, 2022
0
72
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), ...
Jun 6, 2022
0
11
